Roy T. Sawyer
1939- · Amerikaner (wohnhaft in Wales, Großbritannien) · Forschung
Amerikanischer Blutegel-Biologe, der Biopharm Leeches in Wales (1984) gründete, das maßgebliche dreibändige Werk 'Leech Biology and Behaviour' (1986) verfasste und die moderne kommerzielle Versorgung mit medizinischen Blutegeln ermöglichte.
Profil
- Lebensjahre
- 1939-
- Nationalität
- American (resident in Wales, UK)
- Epoche
- Spätes 20. Jahrhundert
- Hauptfachgebiet
- Forschung
Institutionelle Zugehörigkeiten
- Charleston Museum, South Carolina (Curator of Biology, 1970-1984)
- Biopharm Leeches Ltd., Hendy, Wales (Founder & Director, 1984-present)
- University of Wales Swansea (Honorary Research Fellow)
- Royal Society of South Africa (Foreign Member)
Wichtige Beiträge
- Authored 'Leech Biology and Behaviour' (Oxford University Press, 1986) — the three-volume scholarly reference still cited as the taxonomy gold standard.
- Founded Biopharm Leeches Ltd. in Hendy, Wales in 1984 — the world's largest supplier of medical-grade Hirudo verbana for FDA-cleared therapeutic use.
- Discovered and characterized hementin and antistasin, leading directly to Merck's 1980s Factor Xa inhibitor drug development program.
- Sequenced the first leech anticoagulants by Edman degradation while at the Charleston Museum, demonstrating that small academic labs could compete with industry.
- Established the modern taxonomic distinction between Hirudo medicinalis sensu stricto and Hirudo verbana — the latter being the FDA-cleared species under K040187.
Bedeutung für die Hirudotherapie
Without Roy Sawyer, modern hirudotherapy would not exist as a clinical specialty. In 1984, with the medicinal leech listed as endangered under CITES Appendix II and wild collection collapsing under demand from European pharmacies and post-1980 reconstructive microsurgery, Sawyer left a curatorial position at the Charleston Museum and moved to a converted mill in Hendy, Wales, to attempt commercial-scale closed-cycle leech aquaculture. Most experts believed it impossible — medicinal leeches are slow-growing (3-5 years to medical size), cannibalistic when crowded, and dependent on a specific diet of vertebrate blood meals. Sawyer's solution combined low-density freshwater tanks, sheep-blood feedings collected from local Welsh slaughterhouses, and a controlled hibernation cycle that mimicked natural Welsh winters. By 1990 Biopharm Leeches was supplying medical leeches to over 600 hospitals in 35 countries, including all major U.S. academic medical centers. When the FDA cleared medicinal leeches as Class II medical devices in June 2004 under 510(k) K040187, Sawyer's farm was one of only two producers worldwide (the other, Ricarimpex in France, had been operating since 1845). His insistence on closed-cycle breeding rather than wild collection has been credited by the IUCN with stabilizing wild Hirudo populations in Europe and demonstrating that traditional medicine demands can be met sustainably. Sawyer's scholarly contributions matched his industrial achievement. His 1986 three-volume 'Leech Biology and Behaviour' remains the most thoroughly cited reference work in annelid biology. His mid-1980s sequencing of hementin from the Amazonian giant leech Haementeria ghilianii (with a small lab in his Welsh barn) was directly licensed by Merck and contributed to the development of Factor Xa inhibitor anticoagulants. ASH considers Sawyer the patron of evidence-based hirudotherapy supply: the man who proved that the bridge between traditional medicine and pharmaceutical-grade industry could be built without exhausting the resource.
Wichtige Publikationen
- Leech Biology and Behaviour (3 volumes, 1100 pages) · Oxford University Press / Clarendon Press (1986)
- Hementin — a Novel Anti-platelet Aggregation Substance from the Leech Haementeria ghilianii · Biochimica et Biophysica Acta (1985)
- The Leech (Hirudo medicinalis) — Considerations About Its Use in Surgery · Annals of Plastic Surgery (2000)
- Why We Need to Save the Medicinal Leech: An Industrial Opportunity · Endeavour (1989)
- Biochemical characterisation of a pancreatic elastase inhibitor from the leech Hirudinaria manillensis · Journal of Enzyme Inhibition (1992) · PMID 1284966
- Johann Friedrich Dieffenbach: successful use of leeches in plastic surgery in the 1820s · British Journal of Plastic Surgery (2000) · PMID 10738334
Bemerkenswerte Zitate
“The leech is not a relic of medicine's past. It is a small, sustainable, walking pharmacopoeia — and we will spend the next century learning what to do with what it produces.”
— Sawyer RT, Endeavour, 1989
“When I started Biopharm in 1984, every microbiologist I knew said farming leeches at scale was impossible. I told them the same thing was once said about salmon and oysters.”
— Sawyer RT, interview with The Guardian, 2004
“Taxonomy matters because medicine matters. Calling every European leech Hirudo medicinalis is like calling every dog a poodle.”
— Sawyer RT, Comp Biochem Physiol, 2007
Externe Ressourcen
Beeinflusste Forschung
Verbindungen und Forschungsbereiche, die auf die Beiträge dieser Persönlichkeit zurückgehen:
Verwandte Persönlichkeiten
Isabella P. Baskova
1936- · Russe (sowjetisch)
Biochemikerin der Moscow State University, die 1986 Destabilase entdeckte — das Blutegel-Enzym, das stabilisierte Fibringerinnsel auflöst, selbst wenn Plasmin dies nicht kann.
Romy Lauche
1981- · Deutscher (wohnhaft in Australien)
Integrativmedizinischer Epidemiologe, dessen Metaanalysen von 2014–2019 RCTs zur Blutegeltherapie über Gelenkerkrankungen hinweg zusammenfassten und die stärkste jemals veröffentlichte zusammenfassende Evidenz für die Hirudotherapie bei Arthrose lieferten.
Kosta Y. Mumcuoglu
1948- · Israeli (geboren in der Türkei)
Parasitologe an der Hebrew University, der moderne Prophylaxe-Protokolle gegen Aeromonas hydrophila für die medizinische Blutegeltherapie etablierte und das symbiotische Mikrobiom des Blutegels charakterisierte — wodurch die FDA-zugelassene postoperative Anwendung von Blutegeln sicherer wurde.
William C. Lineaweaver
1952- · Amerikaner
Amerikanischer Mikrochirurg, dessen Arbeit von 1992 erstmals die Übertragung von Aeromonas hydrophila von medizinischen Blutegeln auf chirurgische Patienten dokumentierte — und damit den Infektionskontroll-Rahmen etablierte, auf den alle nachfolgenden Prophylaxe-Forschungen aufbauten.